Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.43 |
| ▸ | CA1 | P00915 | 13/20 | 0.43 |
| ▸ | CA2 | P00918 | 13/20 | 0.43 |
| ▸ | CA4 | P22748 | 6/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568957 | 0.86 | CA12 (0.42) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL3533820 | 0.81 | CA12 (0.43) | CA12CA1CA2 | |
| SCHEMBL27716502 | 0.80 | CYP1A2 (0.49) | CA1CA2 | |
| SCHEMBL3530911 | 0.78 | CA2 (0.46) | CA2 | |
| SCHEMBL3533498 | 0.77 | PTPN1 (0.47) | CA12 | |
| SCHEMBL3568963 | 0.77 | HDAC1 (0.41) | L3MBTL1 | |
| SCHEMBL4689420 | 0.74 | NPC1 (0.36) | CA1CA2L3MBTL1 | |
| SCHEMBL3533818 | 0.74 | SMN1; SMN2 (0.41) | L3MBTL1 | |
| SCHEMBL2479873 | 0.71 | LMNA (0.59) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL2693605 | 0.71 | CYP1A2 (0.56) | CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | CA12 4661/4885CA1 3744/4885CA2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.